2. Search Result
Search Result
Results for "

coronary blood flow

" in MedChemExpress (MCE) Product Catalog:
Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-A0168
    Regadenoson
    3 Publications Verification

    CVT-3146

    		 Adenosine Receptor Cardiovascular Disease Cancer
    Regadenoson (CVT-3146) is a selective A2A adenosine receptor agonist and vasodilator that increases coronary blood flow, can be used in study of myocardial perfusion imaging. Regadenoson also increases the permeability of the blood-brain barrier (BBB) in rodents, can be used to study increased delivery of agents to the human CNS .
    Regadenoson
  • HY-P2824
    Streptokinase, β-hemolytic streptococcus (Lancefield Group C)
    1 Publications Verification

    		 Bacterial Cardiovascular Disease
    Streptokinase, β-hemolytic streptococcus (Lancefield Group C) is a bacteria-derived protein and a plasminogen activator. Streptokinase is widely used for the research of the blood-clotting disorders. Streptokinase improves reperfusion blood flow after coronary artery occlusion .
    Streptokinase, β-hemolytic streptococcus (Lancefield Group C)
  • HY-105209
    Pirsidomine

    		Endogenous Metabolite Cardiovascular Disease
    Pirsidomine is a nitric oxide donor. Pirsidomine is a sydnonimine compound. Pirsidomine can transform into a nitric oxide-releasing metabolite in vivo. Pirsidomine prevents occlusion-induced increase in flow in the non-occluded circumflex coronary artery and significantly reduces the blood flow in non-ischemic areas in myocardial infarction dog model. Pirsidomine can be studied in research on cardiovascular diseases .
    Pirsidomine
  • HY-A0113
    Cilazaprilat

    Ro 31-3113

    		 Angiotensin-converting Enzyme (ACE) Cardiovascular Disease
    Cilazaprilat is an inhibitor of angiotensin-converting enzyme (ACE; IC50=0.7 nM for the rat enzyme) and an active metabolite of Cilazapril (HY-A0043). It decreases creatine kinase release in primary neonatal rat cardiac myocytes in an in vitro model of ischemia-reperfusion injury induced by hypoxia and reoxygenation when used at a concentration of 10 μM.3 Intra-arterial administration of cilazaprilat (3 μg/kg per minute) increases coronary blood flow and fractional shortening in a dog model of coronary hypoperfusion-induced myocardial ischemia.
    Cilazaprilat
  • HY-117627
    L 158338

    		Angiotensin Receptor Cardiovascular Disease
    L 158338 is an angiotensin II receptor antagonist. L 158338 alleviates acidosis and increases coronary blood flow during the ischemic period and increases coronary blood flow during the reperfusion period. L 158338 can be used to study myocardial injury during ischemia and reperfusion .
    L 158338
  • HY-18209
    Z-13752A

    		Neprilysin Angiotensin-converting Enzyme (ACE) Cardiovascular Disease
    Z-13752A is a mercaptopropanoyl amino acid. Z-13752A inhibits NEP and ACE, with Ki values of 1.8 and 3.2 nM, respectively. Z-13752A decreases the arterial blood pressure and increases coronary blood flow. Z-13752A can be used in the research of coronary artery occlusion .
    Z-13752A
  • HY-A0168A
    Regadenoson hydrate

    CVT-3146 hydrate

    		 Adenosine Receptor Cardiovascular Disease
    Regadenoson hydrate (NSC 169186) is a selective A2A adenosine receptor agonist and vasodilator that increases coronary blood flow, can be used in study of myocardial perfusion imaging. Regadenoson hydrate also increases the permeability of the blood-brain barrier (BBB) in rodents, can be used to study increased delivery of agents to the human CNS .
    Regadenoson hydrate
  • HY-101390B
    Niguldipine

    		Calcium Channel Cardiovascular Disease
    Niguldipine is a calcium channel blocker with activity in regulating cardiovascular function. Niguldipine can reduce systolic and diastolic blood pressure, thereby increasing heart rate and cardiac output. Niguldipine exhibits dose-dependent and sustained increases in coronary blood flow. Niguldipine also increases perfusion in the kidneys and femoral arteries, but the effect is temporary and to a lesser extent. The effect of Niguldipine on myocardial metabolism is not significant .
    Niguldipine
  • HY-A0168R
    Regadenoson (Standard)

    CVT-3146 (Standard)

    		 Reference Standards Adenosine Receptor Cardiovascular Disease
    Regadenoson (Standard) is the analytical standard of Regadenoson. This product is intended for research and analytical applications. Regadenoson (CVT-3146) is a selective A2A adenosine receptor agonist and vasodilator that increases coronary blood flow, can be used in study of myocardial perfusion imaging. Regadenoson also increases the permeability of the blood-brain barrier (BBB) in rodents, can be used to study increased delivery of agents to the human CNS .
    Regadenoson (Standard)
  • HY-105093
    N 0861

    		Adenosine Receptor Inflammation/Immunology
    N-0861 is a novel selective A1 adenosine receptor antagonist. In studies, it has been shown to be able to inhibit the negative conduction effects (prolonged AH interval) and chest pain caused by adenosine, while having no significant effect on the increase in coronary blood flow velocity caused by adenosine. This indicates that N-0861 has the property of selectively inhibiting A1 adenosine receptors .
    N 0861
  • HY-183138
    N-Demethyldiltiazem

    		Drug Metabolite Cardiovascular Disease
    N-Demethyldiltiazem is a metabolite of Diltiazem (HY-B0632). N-Demethyldiltiazem increases coronary blood flow, modulates cardiac function, decreases systemic blood pressure and heart rate, and alters papillary muscle developed tension .
    N-Demethyldiltiazem
  • HY-118991
    KT-1

    		Adenosine Receptor Cardiovascular Disease
    KT-1 is a vasodilator. KT 1 can decrease aortic pressure, renal blood flow, left ventricular enddiastolic pressure and resistances of total peripheral, vertebral, coronary and renal vasculatures and increase aortic blood flow, vertebral blood flow, coronary blood flow, peak positive left ventricular dP/dt and heart rate in anesthetized open-chest dogs. KT-1 can be used for the research of cardiovascular disease .
    KT-1
  • HY-105646A
    Chromonar hydrochloride

    Carbocromen hydrochloride

    		 Biochemical Assay Reagents Cardiovascular Disease
    Chromonar hydrochloride (Carbocromen hydrochloride) is an orally active, selective long-acting coronary vasodilator. Chromonar hydrochloride increases coronary blood flow. Chromonar hydrochloride is used for the research of angina pectoris .
    Chromonar hydrochloride
  • HY-19066
    KW-3407

    		Potassium Channel Cardiovascular Disease
    KW-3407 is an antiarrhythmic agent. KW-3407 can inhibit two-stage (24 and 48 h) coronary ligation-, digitalis- and adrenaline-induced spontaneously occurring arrhythmias with IC50 values of 18.1, 14.4, 18.3 and 21.4 μg/mL. KW-3407 can decrease the sinoatrial rate and contractile force, and increase the coronary blood flow and AV conduction times .
    KW-3407

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: